Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
9Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
CG Oncology, Inc. (CGON) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
1Distinct source URLs
6High confidence
0.759Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
CG Oncology, Inc. Suppliers
Ticker
Name
Confidence
Evidence
BIOVIRE
BIOVIRE
92%
Prior to becoming a majority-owned subsidiary, Biovire was a vendor to the Company and continues to provide clinical supply of cretostimogene used in the Company’s clinical trials.
Reciprocal relationship from AURA graph: Reciprocal relationship from CGON graph: Reciprocal relationship from AURA graph: Reciprocal relationship from CGON graph: Reciprocal relationship from AURA g…
CG Oncology, Inc. Customers
Ticker
Name
Confidence
Evidence
KISSEI
KISSEI
90%
The Company evaluated the Kissei Territory specific license and related activities under ASC 606, as these transactions are considered transactions with a customer, and identified two material promis…
SP-HEALTHCARE-SPV-I-LLC
SP-HEALTHCARE-SPV-I-LLC
85%
Healthcare, LLC (SafeGuard), purchased a $26.8 million convertible note, including accrued interest, from SP Healthcare SPV I, LLC (the SPV). The SPV used the proceeds from the Note to invest and acq…
Reciprocal relationship from BDRX graph: Reciprocal relationship from CGON graph: Reciprocal relationship from BDRX graph: l lawsuits challenging state authority to regulate prescription drug payment…
Reciprocal relationship from TOVX graph: prescribe legally available drugs for off-label uses, drugs may be marketed only for the approved indications and in accordance with the provisions of the app…
COLLABORATION-AGREEMENTS-LEPU-BIOTECH-CO-LTD
COLLABORATION-AGREEMENTS-LEPU-BIOTECH-CO-LTD
62%
o ANI’s unjust enrichment claim. On July 29, 2025, a jury entered a verdict in favor of the Company, unanimously rejecting all of ANI's claims for unjust enrichment damages. As a result, the Company …
HEALTHCARE-LLC
HEALTHCARE-LLC
62%
Healthcare, LLC (SafeGuard), purchased a $26.8 million convertible note, including accrued interest, from SP Healthcare SPV I, LLC (the SPV). The SPV used the proceeds from the Note to invest and acq…
KISSEI-PHARMACEUTICAL-CO-LTD
KISSEI-PHARMACEUTICAL-CO-LTD
62%
nt) and obtained control of both the SPV and Biovire. As a result of this change in control, the operations of Biovire were consolidated as of the effective date of the conversion. We believe, based …
LEPU-BIOTECH-CO-LTD
LEPU-BIOTECH-CO-LTD
62%
nt) and obtained control of both the SPV and Biovire. As a result of this change in control, the operations of Biovire were consolidated as of the effective date of the conversion. We believe, based …
SAFEGUARD-HEALTHCARE-LLC
SAFEGUARD-HEALTHCARE-LLC
62%
ting cretostimogene in combination with gemcitabine in both the high-risk BCG-exposed and BCG-unresponsive population. Based on internal research derived from NIH SEER database, secondary claims data…
CG Oncology, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CGON-DEBT
Debt stack $3.0M
90%
Market cache reports total debt of $3.0M.
CGON-DEBT-8613
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
CG Oncology, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for CG Oncology, Inc..
CG Oncology, Inc. Ownership
Holder
Name
Confidence
Evidence
CGON-OWNER-RTW-INVESTMENTS-LP
RTW INVESTMENTS, LP
90%
13F overlay lists RTW INVESTMENTS, LP as top holder; 239 tracked holders.
